Oracle recently announced that it agreed to buy Relsys International Inc, a leading vendor for Drug Safety and Risk analysis solution for Health Care Industry. Despite the economic downturn, Oracle ventured out for the buyout of the pharmacology software firm. It gives Oracle to expand its domain knowledge in the vertical of Health care Industry.
As per the Senior VP of Oracle Health Science, the acquisition will improve Health Science Industries for collection, monitoring and analysis of safety data and help to manage safety risk. The customer will be able to gauge the safety risk during the initial stage of development. The software further enables the companies for post production surveillance with better risk management strategy.
The transaction is subject to customary closing condition and and is expected to close in the first half of calendar year 2009.
Filed under Biomedicine, Enterprise Software, M & A | Tags: Health Science, Oracle, Relsys, Risk Analysis | Comment Below
“Identifying safety issues earlier in the development process can significantly reduce the costs and risks associated with bringing drugs and devices to market,” said Dave Bajaj, President and CEO of Relsys. “Industry leaders trust Relsys’ solutions to help them capture these benefits. We look forward to joining Oracle and helping provide the health sciences industry with the most complete, open and integrated suite of enterprise software.”